A prospective, randomised, open-label study to evaluate the bedtime dosing of fimasartan compared to morning dosing effects on blood pressure and urinary albumin excretion

Trial Profile

A prospective, randomised, open-label study to evaluate the bedtime dosing of fimasartan compared to morning dosing effects on blood pressure and urinary albumin excretion

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Fimasartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 New trial record
    • 29 Sep 2016 Results presented at the 26th Scientific Meeting of the International Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top